Ketoconazole treatment of nonprimary coccidioidomycosis: Evaluation of 60 patients during three years of study

Sixty patients with coccidioidomycosis were treated with ketoconazole rather than with another antifungal agent, and their responses were evaluated in relation to the predominant site of Involvement. For the three main groups, improvement occurred in 12 of 19 patients with chronic pulmonary infectio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of medicine 1982-04, Vol.72 (4), p.681-687
Hauptverfasser: DeFelice, Richard, Galgiani, John N., Campbell, Sammy C., Palpant, Samuel D., Friedman, Barry A., Dodge, Russell R., Weinberg, Melvin G., Lincoln, Lawrence J., Tennican, Patrick O., Barbee, Robert A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 687
container_issue 4
container_start_page 681
container_title The American journal of medicine
container_volume 72
creator DeFelice, Richard
Galgiani, John N.
Campbell, Sammy C.
Palpant, Samuel D.
Friedman, Barry A.
Dodge, Russell R.
Weinberg, Melvin G.
Lincoln, Lawrence J.
Tennican, Patrick O.
Barbee, Robert A.
description Sixty patients with coccidioidomycosis were treated with ketoconazole rather than with another antifungal agent, and their responses were evaluated in relation to the predominant site of Involvement. For the three main groups, improvement occurred in 12 of 19 patients with chronic pulmonary infections, in 20 of 23 with soft tissue lesions and in six of 11 with skeletal involvement. Infections in soft tissues improved most rapidly (average of 34 days) and often with 200 mg per day, whereas pulmonary and skeletal infections improved more slowly (63 and 165 days, respectively), usually requiring 400 mg per day. Of 12 patients with response in whom therapy has been discontinued, seven have had relapses. Recurrence was apparent usually within the first month and after six months or less of treatment. Patients in remission had received ketoconazole for six to 17 months. Untoward drug effects included abdominal complaints (23 percent) and gynecomastia (8 percent). Therapy was discontinued in only three patients for side effects. Our findings support the use of ketoconazole in the treatment of certain forms of chronic coccidioidal infections.
doi_str_mv 10.1016/0002-9343(82)90480-6
format Article
fullrecord <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmed_primary_6280499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002934382904806</els_id><sourcerecordid>0002934382904806</sourcerecordid><originalsourceid>FETCH-LOGICAL-e176t-d0ee3a349988c884f3e11b99ff762291b078434765f2a6abf691f36d11db6acc3</originalsourceid><addsrcrecordid>eNo9UE1LxDAUDKKs6-o_UMhRD9WkadPEgyDL-oELXvQc0uRVI9tmadKF-utN2cXTMMy8x8wgdEnJLSWU3xFC8kyygl2L_EaSQpCMH6E5LcsyqyjPj9H833KKzkL4SZTIks_QjOeCFFLOUfcG0Rvf6V-_ARx70LGFLmLf4M532961uh-x8cY467yzvh2NDy7c49VObwYdne8mMyd4m0g6DdgOveu-cPzuAfAIug-TI8TBjufopNGbABcHXKDPp9XH8iVbvz-_Lh_XGdCKx8wSAKZZSiiEEaJoGFBaS9k0Fc9zSWtSiYIVFS-bXHNdN1zShnFLqa25NoYt0NX-73aoW7DqUEQdeif9Ya9DCrFz0KtgUngD1vVgorLeKUrUtLOaRlTTiEoknHZWnP0B4FlwvA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ketoconazole treatment of nonprimary coccidioidomycosis: Evaluation of 60 patients during three years of study</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>DeFelice, Richard ; Galgiani, John N. ; Campbell, Sammy C. ; Palpant, Samuel D. ; Friedman, Barry A. ; Dodge, Russell R. ; Weinberg, Melvin G. ; Lincoln, Lawrence J. ; Tennican, Patrick O. ; Barbee, Robert A.</creator><creatorcontrib>DeFelice, Richard ; Galgiani, John N. ; Campbell, Sammy C. ; Palpant, Samuel D. ; Friedman, Barry A. ; Dodge, Russell R. ; Weinberg, Melvin G. ; Lincoln, Lawrence J. ; Tennican, Patrick O. ; Barbee, Robert A.</creatorcontrib><description>Sixty patients with coccidioidomycosis were treated with ketoconazole rather than with another antifungal agent, and their responses were evaluated in relation to the predominant site of Involvement. For the three main groups, improvement occurred in 12 of 19 patients with chronic pulmonary infections, in 20 of 23 with soft tissue lesions and in six of 11 with skeletal involvement. Infections in soft tissues improved most rapidly (average of 34 days) and often with 200 mg per day, whereas pulmonary and skeletal infections improved more slowly (63 and 165 days, respectively), usually requiring 400 mg per day. Of 12 patients with response in whom therapy has been discontinued, seven have had relapses. Recurrence was apparent usually within the first month and after six months or less of treatment. Patients in remission had received ketoconazole for six to 17 months. Untoward drug effects included abdominal complaints (23 percent) and gynecomastia (8 percent). Therapy was discontinued in only three patients for side effects. Our findings support the use of ketoconazole in the treatment of certain forms of chronic coccidioidal infections.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/0002-9343(82)90480-6</identifier><identifier>PMID: 6280499</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Bone Diseases - drug therapy ; Coccidioidomycosis - drug therapy ; Dermatomycoses - drug therapy ; Humans ; Imidazoles - administration &amp; dosage ; Imidazoles - adverse effects ; Imidazoles - therapeutic use ; Ketoconazole ; Lung Diseases, Fungal - drug therapy ; Meningitis - drug therapy ; Peritoneal Diseases - drug therapy ; Piperazines - administration &amp; dosage ; Piperazines - adverse effects ; Piperazines - therapeutic use</subject><ispartof>The American journal of medicine, 1982-04, Vol.72 (4), p.681-687</ispartof><rights>1982</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0002-9343(82)90480-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6280499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DeFelice, Richard</creatorcontrib><creatorcontrib>Galgiani, John N.</creatorcontrib><creatorcontrib>Campbell, Sammy C.</creatorcontrib><creatorcontrib>Palpant, Samuel D.</creatorcontrib><creatorcontrib>Friedman, Barry A.</creatorcontrib><creatorcontrib>Dodge, Russell R.</creatorcontrib><creatorcontrib>Weinberg, Melvin G.</creatorcontrib><creatorcontrib>Lincoln, Lawrence J.</creatorcontrib><creatorcontrib>Tennican, Patrick O.</creatorcontrib><creatorcontrib>Barbee, Robert A.</creatorcontrib><title>Ketoconazole treatment of nonprimary coccidioidomycosis: Evaluation of 60 patients during three years of study</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>Sixty patients with coccidioidomycosis were treated with ketoconazole rather than with another antifungal agent, and their responses were evaluated in relation to the predominant site of Involvement. For the three main groups, improvement occurred in 12 of 19 patients with chronic pulmonary infections, in 20 of 23 with soft tissue lesions and in six of 11 with skeletal involvement. Infections in soft tissues improved most rapidly (average of 34 days) and often with 200 mg per day, whereas pulmonary and skeletal infections improved more slowly (63 and 165 days, respectively), usually requiring 400 mg per day. Of 12 patients with response in whom therapy has been discontinued, seven have had relapses. Recurrence was apparent usually within the first month and after six months or less of treatment. Patients in remission had received ketoconazole for six to 17 months. Untoward drug effects included abdominal complaints (23 percent) and gynecomastia (8 percent). Therapy was discontinued in only three patients for side effects. Our findings support the use of ketoconazole in the treatment of certain forms of chronic coccidioidal infections.</description><subject>Bone Diseases - drug therapy</subject><subject>Coccidioidomycosis - drug therapy</subject><subject>Dermatomycoses - drug therapy</subject><subject>Humans</subject><subject>Imidazoles - administration &amp; dosage</subject><subject>Imidazoles - adverse effects</subject><subject>Imidazoles - therapeutic use</subject><subject>Ketoconazole</subject><subject>Lung Diseases, Fungal - drug therapy</subject><subject>Meningitis - drug therapy</subject><subject>Peritoneal Diseases - drug therapy</subject><subject>Piperazines - administration &amp; dosage</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - therapeutic use</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UE1LxDAUDKKs6-o_UMhRD9WkadPEgyDL-oELXvQc0uRVI9tmadKF-utN2cXTMMy8x8wgdEnJLSWU3xFC8kyygl2L_EaSQpCMH6E5LcsyqyjPj9H833KKzkL4SZTIks_QjOeCFFLOUfcG0Rvf6V-_ARx70LGFLmLf4M532961uh-x8cY467yzvh2NDy7c49VObwYdne8mMyd4m0g6DdgOveu-cPzuAfAIug-TI8TBjufopNGbABcHXKDPp9XH8iVbvz-_Lh_XGdCKx8wSAKZZSiiEEaJoGFBaS9k0Fc9zSWtSiYIVFS-bXHNdN1zShnFLqa25NoYt0NX-73aoW7DqUEQdeif9Ya9DCrFz0KtgUngD1vVgorLeKUrUtLOaRlTTiEoknHZWnP0B4FlwvA</recordid><startdate>198204</startdate><enddate>198204</enddate><creator>DeFelice, Richard</creator><creator>Galgiani, John N.</creator><creator>Campbell, Sammy C.</creator><creator>Palpant, Samuel D.</creator><creator>Friedman, Barry A.</creator><creator>Dodge, Russell R.</creator><creator>Weinberg, Melvin G.</creator><creator>Lincoln, Lawrence J.</creator><creator>Tennican, Patrick O.</creator><creator>Barbee, Robert A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>198204</creationdate><title>Ketoconazole treatment of nonprimary coccidioidomycosis: Evaluation of 60 patients during three years of study</title><author>DeFelice, Richard ; Galgiani, John N. ; Campbell, Sammy C. ; Palpant, Samuel D. ; Friedman, Barry A. ; Dodge, Russell R. ; Weinberg, Melvin G. ; Lincoln, Lawrence J. ; Tennican, Patrick O. ; Barbee, Robert A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e176t-d0ee3a349988c884f3e11b99ff762291b078434765f2a6abf691f36d11db6acc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Bone Diseases - drug therapy</topic><topic>Coccidioidomycosis - drug therapy</topic><topic>Dermatomycoses - drug therapy</topic><topic>Humans</topic><topic>Imidazoles - administration &amp; dosage</topic><topic>Imidazoles - adverse effects</topic><topic>Imidazoles - therapeutic use</topic><topic>Ketoconazole</topic><topic>Lung Diseases, Fungal - drug therapy</topic><topic>Meningitis - drug therapy</topic><topic>Peritoneal Diseases - drug therapy</topic><topic>Piperazines - administration &amp; dosage</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DeFelice, Richard</creatorcontrib><creatorcontrib>Galgiani, John N.</creatorcontrib><creatorcontrib>Campbell, Sammy C.</creatorcontrib><creatorcontrib>Palpant, Samuel D.</creatorcontrib><creatorcontrib>Friedman, Barry A.</creatorcontrib><creatorcontrib>Dodge, Russell R.</creatorcontrib><creatorcontrib>Weinberg, Melvin G.</creatorcontrib><creatorcontrib>Lincoln, Lawrence J.</creatorcontrib><creatorcontrib>Tennican, Patrick O.</creatorcontrib><creatorcontrib>Barbee, Robert A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DeFelice, Richard</au><au>Galgiani, John N.</au><au>Campbell, Sammy C.</au><au>Palpant, Samuel D.</au><au>Friedman, Barry A.</au><au>Dodge, Russell R.</au><au>Weinberg, Melvin G.</au><au>Lincoln, Lawrence J.</au><au>Tennican, Patrick O.</au><au>Barbee, Robert A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ketoconazole treatment of nonprimary coccidioidomycosis: Evaluation of 60 patients during three years of study</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>1982-04</date><risdate>1982</risdate><volume>72</volume><issue>4</issue><spage>681</spage><epage>687</epage><pages>681-687</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><abstract>Sixty patients with coccidioidomycosis were treated with ketoconazole rather than with another antifungal agent, and their responses were evaluated in relation to the predominant site of Involvement. For the three main groups, improvement occurred in 12 of 19 patients with chronic pulmonary infections, in 20 of 23 with soft tissue lesions and in six of 11 with skeletal involvement. Infections in soft tissues improved most rapidly (average of 34 days) and often with 200 mg per day, whereas pulmonary and skeletal infections improved more slowly (63 and 165 days, respectively), usually requiring 400 mg per day. Of 12 patients with response in whom therapy has been discontinued, seven have had relapses. Recurrence was apparent usually within the first month and after six months or less of treatment. Patients in remission had received ketoconazole for six to 17 months. Untoward drug effects included abdominal complaints (23 percent) and gynecomastia (8 percent). Therapy was discontinued in only three patients for side effects. Our findings support the use of ketoconazole in the treatment of certain forms of chronic coccidioidal infections.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>6280499</pmid><doi>10.1016/0002-9343(82)90480-6</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9343
ispartof The American journal of medicine, 1982-04, Vol.72 (4), p.681-687
issn 0002-9343
1555-7162
language eng
recordid cdi_pubmed_primary_6280499
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Bone Diseases - drug therapy
Coccidioidomycosis - drug therapy
Dermatomycoses - drug therapy
Humans
Imidazoles - administration & dosage
Imidazoles - adverse effects
Imidazoles - therapeutic use
Ketoconazole
Lung Diseases, Fungal - drug therapy
Meningitis - drug therapy
Peritoneal Diseases - drug therapy
Piperazines - administration & dosage
Piperazines - adverse effects
Piperazines - therapeutic use
title Ketoconazole treatment of nonprimary coccidioidomycosis: Evaluation of 60 patients during three years of study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A31%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ketoconazole%20treatment%20of%20nonprimary%20coccidioidomycosis:%20Evaluation%20of%2060%20patients%20during%20three%20years%20of%20study&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=DeFelice,%20Richard&rft.date=1982-04&rft.volume=72&rft.issue=4&rft.spage=681&rft.epage=687&rft.pages=681-687&rft.issn=0002-9343&rft.eissn=1555-7162&rft_id=info:doi/10.1016/0002-9343(82)90480-6&rft_dat=%3Celsevier_pubme%3E0002934382904806%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6280499&rft_els_id=0002934382904806&rfr_iscdi=true